Description: Biotron Limited, a biotechnology company, develops and commercializes novel small molecule antiviral therapeutics to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. The company also has a portfolio of preclinical antiviral programs developing drugs targeting a range of viruses, including dengue, ebola, influenza, and zika, as well as Middle East respiratory virus. Biotron Limited is based in North Ryde, Australia.
Home Page: www.biotron.com.au
66 Hunter Street
Sydney,
NSW
2000
Australia
Phone:
61 2 9300 3344
Officers
| Name | Title |
|---|---|
| Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D. | MD & Exec. Director |
| Mr. Peter James Nightingale B.Econ, CA | Company Sec. |
| Dr. Stephen L. Becker M.D. | Chief Medical Officer |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 23.6052 |
| Price-to-Sales TTM: | 11.1691 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |